Endothelium-dependent relaxation of mesenteric resistance arteries of spontaneously hypertensive rats (SHRs) and normotensive Wistar-Kyoto (WKY) rats was studied. Acetylcholine-induced relaxation of SHR vessels precontracted with 10 gM norepinephrine was endothelium dependent and attenuated compared with WKY vessels. The impaired response of SHR vessels was normalized by inhibition of cyclooxygenase with indomethacin. Blockade of nitric oxide synthetase with NG_nitro L-arginine methyl ester (L-NAME) or inhibition of guanylate cyclase with methylene blue attenuated acetylcholine-induced relaxation of norepinephrine-contracted SHR vessels but had no effect on WKY vessels. When vessels were precontracted with 30 nM arginine vasopressin, acetylcholine induced similar degrees of relaxation in both strains. A similar response was detected when lysine vasopressin was used to induce tone. Indomethacin had no effect on relaxation responses of SHR and WKY vessels precontracted with either form of vasopressin. L-NAME and methylene blue partially inhibited acetylcholine-induced relaxation of vasopressin-contracted vessels from both strains. Acetylcholine added at baseline did not induce contraction of vessels from either strain. It is concluded that endothelium-dependent relaxation of SHR resistance arteries is not impaired under all circumstances. Acetylcholine-induced relaxation may be suppressed in SHR resistance arteries when norepinephrine is used to induce contraction as a result of catecholamine-induced production of an endothelium-derived contracting factor. Vasopressin, on the other hand, does not elicit production of this contracting factor and may enhance the vasorelaxant action of acetylcholine in resistance arteries of both strains via actions on endothelial or vascular smooth muscle cells. (Circulation Research 1993;72:290-296 release other relaxing factors such as the putative endothelium-derived hyperpolarizing factor.11,12 It has previously been demonstrated that acetylcholine-induced relaxation is impaired in resistance arteries of various models of experimental hypertension including genetic,13-'5 renovascular,1617 deoxycorticosterone acetate-salt, 16'18 and coarctation-induced16'19,20 hypertension. A similar defect has been reported in arteries isolated from the aging normotensive rat.2' Among the most studied vessels are arteries of the spontaneously hypertensive rat (SHR), in which it has been observed that the relaxation response to low-dose acetylcholine is impaired and that contraction is induced by high-dose acetylcholine.13-15 In addition, blockade of cyclooxygenase with indomethacin in the SHR vessel normalizes acetylcholine-induced relaxation and eliminates the contractile response to high-dose acetylcholine. [22] [23] [24] [25] From the variety of models in which disturbed endothelium-dependent relaxation has been reported and the fact that the impaired function can be improved by lowering blood pressure,'626 it seems likely that the endothelial dysfunction is caused by the hypertensive state and may contribute to the associated vascular pathology. To assess further the mechanism that underlies the impaired endothelium-dependent relaxation response of resistance arteries of the SHR, we have examined acetylcholine-induced relaxation of vessels by guest on
T he vascular endothelium modulates arterial vascular smooth muscle responsiveness to constrictor and vasodilator agents by the release of endothelium-derived relaxing and contracting factors.1,2 One form of endothelium-derived relaxing factor, nitric oxide, is synthesized from the amino acid L-arginine in endothelial and other cell types in a Ca2+-dependent reaction catalyzed by nitric oxide synthetase.3-7 Nitric oxide is a potent activator of the soluble guanylate cyclase and increases intracellular levels of cGMP in target tissues.8 The nitric oxide synthetase pathway can be inhibited by structural analogues of L-arginine such as NG-nitro L-arginine methyl ester (L-NAME) and can be stimulated by the addition of L-arginine.9,10 In addition to nitric oxide, it is believed that endothelial cells release other relaxing factors such as the putative endothelium-derived hyperpolarizing factor. 11, 12 It has previously been demonstrated that acetylcholine-induced relaxation is impaired in resistance arteries of various models of experimental hypertension including genetic,13-'5 renovascular,1617 deoxycorticosterone acetate-salt,16'18 and coarctation-induced16 '19,20 hypertension. A similar defect has been reported in arteries isolated from the aging normotensive rat.2' Among the most studied vessels are arteries of the spontaneously hypertensive rat (SHR), in which it has been observed that the relaxation response to low-dose acetylcholine is impaired and that contraction is induced by high-dose acetylcholine. [13] [14] [15] In addition, blockade of cyclooxygenase with indomethacin in the SHR vessel normalizes acetylcholine-induced relaxation and eliminates the contractile response to high-dose acetylcholine. [22] [23] [24] [25] From the variety of models in which disturbed endothelium-dependent relaxation has been reported and the fact that the impaired function can be improved by lowering blood pressure,'626 it seems likely that the endothelial dysfunction is caused by the hypertensive state and may contribute to the associated vascular pathology. To assess further the mechanism that underlies the impaired endothelium-dependent relaxation response of resistance arteries of the SHR, we have examined acetylcholine-induced relaxation of vessels Vessel segments were mounted in the chamber of a dual-channel myograph (JP Trading, Aarhus, Denmark, or Midori Cascade, Portland, Ore.) filled with PSS (37°C), which was gassed with 95% 02-5% C02, resulting in a pH of 7.4. After a 30-minute period, the vessels were set to a circumference equivalent to 90% of that which they would have with an intraluminal pressure of 100 mm Hg. 27 Cross-sectional area of the segment was calculated from values of the diameter of the segment, its axial length, and the media volume. 28 In some experiments, the endothelium was removed by gently rubbing the intimal surface of the vessels with a human hair as previously described by our laboratory.29 '30 The absence of a relaxation response to acetylcholine (0.1 ,M) of vessels precontracted with norepinephrine was taken as evidence that the endothelium was functionally disrupted.
Each vessel was then challenged with 100 mM K' (Na+ substituted) and 100 mM K++10 ,uM norepinephrine until reproducible responses were observed. The vessel segments were then induced to contract by the addition of norepinephrine (10 ,uM) , and after the contractile response stabilized, acetylcholine (10 nM-10 uM) was cumulatively added to induce relaxation. After washoutinduced relaxation to baseline, the vessels were induced to contract by the addition of arginine (or lysine) vasopressin (30 nM), and the relaxation response to acetylcholine was redetermined. In some experiments, the relaxation response to acetylcholine was examined only after inducing tone with arginine vasopressin, and the results did not differ from those obtained when contraction was first induced by norepinephrine.
In the course of these studies, it was noted that active tension induced by arginine vasopressin undergoes a spontaneous decay. Experiments were therefore carried out to determine the degree of spontaneous relaxation that would occur during the period of the cumulative addition of acetylcholine. Endothelium-intact or -denuded vessels were mounted in pairs in a myograph After induction of tone with arginine vasopressin, acetylcholine was cumulatively added to one vessel, and at the same time saline was added to the other. Comparisons were then made between the acetylcholine-induced and time-dependent responses of the two vessels.
A series of experiments was performed to determine whether acetylcholine induces contraction when added to resting resistance arteries. The vessels were precontracted with norepinephrine, and relaxation by acetylcholine was induced to assess the functional status of the endothelium. After washout of drugs, acetylcholine was cumulatively added, and the responses were recorded.
Experiments were also performed in the presence of indomethacin (10 gtM) to prevent the production of vasoactive prostanoids. Others were performed in the presence of L-NAME (30 ,uM) to inhibit the nitric oxide synthetase pathway or methylene blue (300 nM) to inhibit guanylate cyclase activity. All drugs were purchased from Sigma Chemical Co., St. Louis, Mo., and prepared in distilled water, with the exception of indomethacin, which was prepared in an equimolar concentration of sodium carbonate.
Statistical Analysis
The extent of acetylcholine-induced relaxation is expressed as percentage of the initial contraction induced by the contractile agonist. All values are given as mean±SEM. Statistical evaluation of the data was performed by analysis of variance with a repeatedmeasures format using the SYSTAT software package (SYSTAT, Inc., Evanston, Ill.). Values of p<0.05 were considered to be statistically significant.
Results
The level of active stress induced by norepinephrine did not differ between vessels of the two strains (SHR, 195 + 18 mN/mm2; WKY, 168±14 mN/mm2; n = 6; p=NS). Nevertheless, WKY vessels relaxed significantly more in response to acetylcholine than SHR vessels ( Figure 1 ), and SHR vessels showed an attenuated relaxation in response to concentrations of acetylcholine greater than 100 nM ( Figure 1 ). Mechanical disruption of the endothelium inhibited acetylcholineinduced relaxation of both WKY and SHR vessels without significantly affecting the maximal active stress response to norepinephrine (Tables 1 and 2 ). We did note, however, that the response to lower doses of norepinephrine was altered by removal of the endothelium; e.g., in the presence of an intact endothelium, SHR vessels responded to 0.3 and 1.0 ,M norepinephrine with a greater percentage of the maximal response than WKY vessels (Table 3) . This difference was ablated by removal of the endothelium.
In contrast to the response with norepinephrine, acetylcholine caused similar degrees of relaxation in SHR and WKY vessels precontracted to similar active stress levels with arginine vasopressin ( 
E(-).
Since contraction induced by vasopressin decayed over time, we performed an experiment to determine the magnitude of the spontaneous relaxation over the period of the cumulative addition of acetylcholine (approximately 10 minutes). Endothelium-intact or -denuded vessels were induced to contract with arginine vasopressin, then either acetylcholine or PSS (control) was added, and the responses were recorded. The results are illustrated in Figure 4 for WKY rats and in Figure 5 for SHRs. For the purpose of comparison, it is useful to focus on the points indicating the addition of 0.3 ,uM acetylcholine. In WKY rats, 0.3 ,M acetylcholine relaxed endothelium-intact vessels more than 95%, whereas endothelium-denuded vessels relaxed approximately 20% (Figure 4 ). In contrast, endothelium-intact WKY vessels spontaneously relaxed approximately 50% over the same time period, whereas endothelium-denuded vessels relaxed approximately 23%. These results indicate that in WKY rats a portion of the spontaneous relaxation of vessels contracted with arginine vasopressin is endothelium dependent. In contrast, although there was approximately a 20% decay of tone in SHR vessels contracted with arginine vasopressin, the decrease was not endothelium dependent, demonstrating a differential response of vessels of the two strains ( Figure 5 ).
When 10 ,uM indomethacin was added to block cyclooxygenase activity, no effect on the maximal active stress response to norepinephrine was detected (Tables  1 and 2 ). In agreement with previous reports, however, pretreatment with indomethacin nearly normalized acetylcholine-induced relaxation of SHR vessels precontracted with norepinephrine ( Figure 6 ). Moreover, indomethacin slightly decreased the sensitivity of WKY vessels to acetylcholine such that no strain differences in the relaxation response were observed ( Figure 6 ). In contrast to norepinephrine, indomethacin significantly depressed the active stress response to arginine vasopressin in WKY vessels (Table 2) . Nevertheless, this inhibitor was without effect on acetylcholine-induced relaxation vessels of both strains when they were precontracted with arginine vasopressin (Figure 7) .
The role of endothelium-generated nitric oxide in these differential responses was assessed by inhibiting nitric oxide synthesis with L-NAME in the presence of indomethacin. No effect of L-NAME on stress responses to either norepinephrine or arginine vasopressin was detected (Tables 1 and 2 ). Moreover, L-NAME, at 30 ,uM, completely inhibited acetylcholine-induced relaxation of SHR vessels precontracted with norepinephrine and was without effect on WKY vessels (Figure 8) . When SHR vessels were precontracted with arginine vasopressin, L-NAME inhibited acetylcholineinduced relaxation by more than 50%. The response of WKY vessels precontracted with vasopressin, however, was different from those precontracted with norepinephrine in that L-NAME partially blocked the relaxation response to acetylcholine (Figure 9) . A similar 
effect of L-NAME was observed when vessels were precontracted with lysine vasopressin (data not shown).
As an additional test of the role of nitric oxide in these responses, the effect of methylene blue, an inhibitor of the soluble guanylate cyclase, was examined in the presence of indomethacin. Methylene blue had no effect on the maximal stress responses to norepinephrine or arginine vasopressin (Tables 1 and 2 ). Furthermore, the responses observed in the presence of methylene blue were nearly identical to those observed with L-NAME. Methylene blue nearly completely inhibited acetylcholine-induced relaxation of SHR vessels precontracted with norepinephrine (relaxation to There is at least one report that aortic tissue of the SHR contracts in response to acetylcholine and that of the WKY rat does not.'4 However, our finding that acetylcholine-induced relaxation of SHR resistance arteries is normal when prerelaxation tone is induced with arginine vasopressin suggests that acetylcholine does not elicit endothelium-derived contracting factor in the resistance artery. To directly test this, resistance arteries from six rats of each strain were prepared for measurement of contraction, and acetylcholine was cumulatively added. No vessel from either strain contracted in response to acetylcholine (Figure 10 ).
Discussion
The present study confirms previous reports that demonstrated impaired endothelium-dependent relax- SHR, spontaneously hypertensive rats. All experiments were performed in the presence of indomethacin (10 pgM).
*p<0.05 for L-NAME vs. CONT in SHR. +p<0.O5 for L-NAME vs. CONT in WKY ation of resistance arteries of the SHR.13-15 The data also support prior observations that suppressed relaxation of SHR vessels can be normalized by inhibition of the cyclooxygenase pathway.22-25 The latter observation has been widely interpreted to indicate that the reduced relaxation response of SHR resistance arteries results from the production of an endothelium-derived contracting factor.22-25
The major new finding of the present study is that endothelium-dependent relaxation of SHR resistance log [AChI arteries is not impaired under all conditions but appears to be a function of the agonist that is used to preconstrict the vessel. For example, SHR vessels precontracted with norepinephrine exhibit impaired relaxation to acetylcholine, whereas those precontracted with arginine vasopressin have a normal acetylcholine-induced relaxation response (Figures 1 and 2 ). Since no between-strain differences were detected in the magnitude of precontraction induced by norepinephrine or arginine vasopressin, a role for differences in prerelaxation tone can be ruled out. Furthermore, since similar responses were observed for both arginine and lysine vasopressin, the possibility that arginine from the vasopressin molecule serves as substrate for the nitric oxide pathway can be rejected (Figure 3 ). Given these limits, at least two hypotheses can be proposed to explain our observation that impaired relaxation of SHR resistance arteries is a function of the agonist used to induce the precontraction. One is that norepinephrine, but not vasopressin, induces the production of a cyclooxygenase-derived contracting factor in SHR but not WKY vessels. Three lines of evidence support this hypothesis. One is our demonstration that acetylcholine does not induce contraction of endothelium-intact resistance arteries of the rats that we studied ( Figure 10) . A second is our observation that indomethacin normalizes acetylcholine-induced relaxation in SHR vessels that are precontracted with norepinephrine and has no effect during contraction with vasopressin ( Figure 6) . A third is our data indicating that although endothelial denudation does not affect the maximal response to norepinephrine (Tables 1 and 2) , it does alter the response to lower concentrations of the agonist; e.g., the contractile response of SHR vessels to 0.3 and 1 pgM norepinephrine is decreased by endothelial denudation, whereas the response of the WKY vessel is enhanced by endothelial denudation (Table 3) .
Thus, several lines of evidence support the hypothesis that norepinephrine induces the release of a cyclooxygenase-generated endothelium-dependent contracting factor in the SHR but not WKY resistance artery.
Moreover, the effect appears to be nonselective, since endothelium-dependent relaxation has also been shown to be impaired when serotonin or prostaglandin F2, 15, 31 are used to induce tone. The fact that acetylcholine did not induce contraction in the resistance arteries deserves additional comment, since it has been previously demonstrated that acetylcholine induces contraction in aortas of SHRs.14 Obvious differences between the present report and the prior one that may contribute to the differential findings are the vessel types (resistance artery versus conduit artery) and the age of the rats that were studied (13-15 weeks of age in the present study versus 30-34 weeks in Reference 14) .
A second hypothesis that can explain our findings is that arginine vasopressin elicits production of a contracting factor in vessels of both strains, but its action is overcome by either the simultaneous release of a relaxing factor or a direct effect of vasopressin on the smooth muscle cell to promote relaxation. The finding that indomethacin did not further shift the relaxation responses of vasopressin-contracted vessels from either strain indicates that vasopressin does not elicit production of a cyclooxygenase-generated contracting factor ( Figure 7 ). The possibility that arginine vasopressin enhances relaxation via an action on the vascular smooth muscle cell is supported by our finding that the vasopressin-induced contraction shows a component of spontaneous relaxation that at least in WKY vessels is endothelium dependent (Figure 4 ).
The latter point is supported by reports that vasopressin stimulates the endothelium to release dilator substances. For example, Katusic et a132 showed that arginine vasopressin inhibits myogenic tone and induces relaxation of precontracted canine basilar arteries and that removal of the endothelium inhibits these effects. Moreover, Randall et al3 have reported that removal of the endothelium enhances the sensitivity and reactivity of the rat superior mesenteric artery to arginine vasopressin. Finally, Suzuki et al34 have shown that high concentrations of vasopressin induce relaxation in the human forearm through a mechanism that is not mediated by prostaglandins. Thus, it seems likely that in addition to a direct effect on vascular muscle, vasopressin stimulates the production of endothelium-derived factors to promote relaxation.
Also of interest is our observation that acetylcholineinduced relaxation of SHR vessels precontracted with norepinephrine was inhibited by L-NAME, whereas this blocker of nitric oxide synthetase was without effect on WKY vessels. One possible explanation is that vessels of the two strains have differing sensitivities to L-NAME. Since L-NAME is a competitive metabolic inhibitor, this could imply that either the nitric oxide synthetase enzyme differs between the two strains or that the metabolic availability of L-arginine is significantly different. At the present time we cannot distinguish between these possibilities.
Finally, the results of our experiments may have important implications for endothelium-associated vascular pathology of hypertension. They indicate that impaired endothelial function may contribute to vascular tone in hypertensive states associated with raised catecholamine levels (i.e., the early hypertensive state) but would have little effect when peripheral resistance is enhanced by elevated production of vasopressin (i.e., during sodium loading). 35 
